A new study published in the Journal of Cardiovascular Ultrasound revealed a new parameter linked to right ventricular function as a good prognostic tool for pulmonary arterial hypertension (PAH). The study is entitled “Impaired Global Right Ventricular Longitudinal Strain Predicts Long-Term Adverse Outcomes in…
News
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company focused on addressing rare, chronic, and serious inflammatory and fibrotic diseases, recently announced that the US Food and Drug Administration has granted its orally-available CB2 receptor agonist Resunab Fast Track Development status for systemic sclerosis. With the FDA’s Fast Track Designation, Corbus will be…
Researchers at the University of Alberta in Canada published an article in the journal Cell Metabolism concerning pulmonary arterial hypertension (PAH) and details on a new theory suggesting that the disorder should be seen as a syndrome affecting several organs at the metabolic level. The study…
A new study led by researchers at Peking Union Medical College Hospital in China recently revealed that resveratrol can prevent pulmonary arterial hypertension (PAH) through a protein called SIRT1 (silence information regulator 1) in vitro and in rat models. The study was published in the journal…
A study recently published in the International Journal of Chronic Obstructive Pulmonary Disease emphasized that patients with arterial hypertension can be considered a risk group for chronic obstructive pulmonary disease (COPD) and should be screened for the disorder even in the absence of respiratory symptoms. The study…
An international group of researchers are currently recruiting participants for Sanofi’s Phase 2 trial of SAR156597 for the treatment of idiopathic pulmonary fibrosis (IPF). The official title of the trial, which is now listed at ClinicalTrials.gov, is “Efficacy and Safety of SAR156597 in the Treatment of Idiopathic…
A study led by researchers at the Imperial College London in the United Kingdom was recently published in the journal Nature reporting the discovery of a gene involved in pulmonary hypertension pathology. The study is entitled “The zinc transporter ZIP12 regulates the pulmonary…
Genentech recently announced in a statement that Esbriet (pirfenidone) has been recommended in the new American Thoracic Society’s (ATS) idiopathic pulmonary fibrosis (IPF) treatment guidelines. This recommendation, which is published as a resource for clinicians, is conditional and the ATS notes that healthcare providers should always discuss the pros…
In a new study entitled “Trends in Hospitalization for Pediatric Pulmonary Hypertension,” researchers performed a retrospective study where they analyzed data concerning hospitalizations of children with pulmonary hypertension. The study was published in the journal Pediatrics. Pulmonary hypertension is a condition in which high blood pressure…
A team led by researchers at the University of Texas Southwestern Medical Center recently published in the journal Circulation: Heart Failure that patients with pulmonary hypertension can benefit from exercise training. The study is entitled “Efficacy and Safety of Exercise Training in Chronic…
A variety of biomarkers are elevated in the serum of patients with systemic sclerosis-pulmonary arterial hypertension (SSc-PAH). Researchers have mostly been studying these markers to determine if they can be used to help diagnose SSc-PAH or if they can serve as targets for new treatments. Alternatively, a study from Northwestern…
Results from a recent study published in the journal Advance Therapy, showed that pirfenidone (known by the brand name Esbriet from Roche) is effective and has a safety profile consistent with those seen in the Phase III clinical study ASCEND for the treatment of IPF. According to…
